title: Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
abstract: BACKGROUND
  New WHO guidelines recommend ART initiation for HIV-positive persons with CD4 cell counts ≤500 cells/µL, a higher threshold than was previously recommended. Country decision makers must consider whether to further expand ART eligibility accordingly.
  
  
  METHODS
  We used multiple independent mathematical models in four settings-South Africa, Zambia, India, and Vietnam-to evaluate the potential health impact, costs, and cost-effectiveness of different adult ART eligibility criteria under scenarios of current and expanded treatment coverage, with results projected over 20 years. Analyses considered extending eligibility to include individuals with CD4 ≤500 cells/µL or all HIV-positive adults, compared to the previous recommendation of initiation with CD4 ≤350 cells/µL. We assessed costs from a health system perspective, and calculated the incremental cost per DALY averted ($/DALY) to compare competing strategies. Strategies were considered 'very cost-effective' if the $/DALY was less than the country's per capita gross domestic product (GDP; South Africa: $8040, Zambia: $1425, India: $1489, Vietnam: $1407) and 'cost-effective' if $/DALY was less than three times per capita GDP.
  
  
  RESULTS
  In South Africa, the cost per DALY averted of extending ART eligibility to CD4 ≤500 cells/µL ranged from $237 to $1691/DALY compared to 2010 guidelines; in Zambia, expanded eligibility ranged from improving health outcomes while reducing costs (i.e. dominating current guidelines) to $749/DALY. Results were similar in scenarios with substantially expanded treatment access and for expanding eligibility to all HIV-positive adults. Expanding treatment coverage in the general population was therefore found to be cost-effective. In India, eligibility for all HIV-positive persons ranged from $131 to $241/DALY and in Vietnam eligibility for CD4 ≤500 cells/µL cost $290/DALY. In concentrated epidemics, expanded access among key populations was also cost-effective.
  
  
  CONCLUSIONS
  Earlier ART eligibility is estimated to be very cost-effective in low- and middle-income settings, although these questions should be revisited as further information becomes available. Scaling-up ART should be considered among other high-priority health interventions competing for health budgets.
  
  
  BACKGROUND
  The Bill and Melinda Gates Foundation and World Health Organization.
authors.affiliation: Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Eaton
authors.affiliation: Center for Health Decision Science, Harvard School of Public Health, Boston, MA, USA.
authors.forename: Nicolas A
authors.initials: NA
authors.lastname: Menzies
authors.affiliation: Futures Institute, Glastonbury, CT, USA.
authors.forename: John
authors.initials: J
authors.lastname: Stover
authors.affiliation: Research Department of Infection and Population Health, University College London, London, UK.
authors.forename: Valentina
authors.initials: V
authors.lastname: Cambiano
authors.affiliation: Department of Global Health and Population, Harvard School of Public Health, Boston, MA, USA.
authors.forename: Leonid
authors.initials: L
authors.lastname: Chindelevitch
authors.affiliation: MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
authors.forename: Anne
authors.initials: A
authors.lastname: Cori
authors.affiliation: Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands ; Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa ; Nijmegen International Center for Health System Analysis and Education (NICHE), Department of Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
authors.forename: Jan A C
authors.initials: JA
authors.lastname: Hontelez
authors.affiliation: Harvard School of Public Health, Boston, MA, USA.
authors.forename: Salal
authors.initials: S
authors.lastname: Humair
authors.affiliation: Kirby Institute, University of New South Wales, Sydney, Australia.
authors.forename: Cliff C
authors.initials: CC
authors.lastname: Kerr
authors.affiliation: Epidemiological Modeling Group, Intellectual Ventures Laboratory, Bellevue, WA, USA.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Klein
authors.affiliation: Department of Infectious Disease Epidemiology, Imperial College London, London, UK ; Division of Infectious Diseases, St. Michael's Hospital, University of Toronto, Canada.
authors.forename: Sharmistha
authors.initials: S
authors.lastname: Mishra
authors.affiliation: Social and Mathematical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
authors.forename: Kate M
authors.initials: KM
authors.lastname: Mitchell
authors.affiliation: Department of Virology, Erasmus Medical Center, Rotterdam, Netherlands.
authors.forename: Brooke E
authors.initials: BE
authors.lastname: Nichols
authors.affiliation: Social and Mathematical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Vickerman
authors.affiliation: Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
authors.forename: Roel
authors.initials: R
authors.lastname: Bakker
authors.affiliation: Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa ; Harvard School of Public Health, Boston, MA, USA.
authors.forename: Till
authors.initials: T
authors.lastname: Bärnighausen
authors.affiliation: Epidemiological Modeling Group, Intellectual Ventures Laboratory, Bellevue, WA, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Bershteyn
authors.affiliation: Harvard School of Public Health, Boston, MA, USA.
authors.forename: David E
authors.initials: DE
authors.lastname: Bloom
authors.affiliation: Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Boily
authors.affiliation: Epidemiological Modeling Group, Intellectual Ventures Laboratory, Bellevue, WA, USA.
authors.forename: Stewart T
authors.initials: ST
authors.lastname: Chang
authors.affiliation: Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA ; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
authors.forename: Ted
authors.initials: T
authors.lastname: Cohen
authors.affiliation: Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Dodd
authors.affiliation: MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
authors.forename: Christophe
authors.initials: C
authors.lastname: Fraser
authors.affiliation: Futures Institute, Glastonbury, CT, USA.
authors.forename: Chaitra
authors.initials: C
authors.lastname: Gopalappa
authors.affiliation: Copenhagen University Hospital/Rigshospitalet, Copenhagen, Denmark ; University of Copenhagen, Copenhagen, Denmark.
authors.forename: Jens
authors.initials: J
authors.lastname: Lundgren
authors.affiliation: School of Social and Community Medicine, University of Bristol, Bristol, UK ; Social and Mathematical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
authors.forename: Natasha K
authors.initials: NK
authors.lastname: Martin
authors.affiliation: Nijmegen International Center for Health System Analysis and Education (NICHE), Department of Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
authors.forename: Evelinn
authors.initials: E
authors.lastname: Mikkelsen
authors.affiliation: Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
authors.forename: Elisa
authors.initials: E
authors.lastname: Mountain
authors.affiliation: Kirby Institute, University of New South Wales, Sydney, Australia.
authors.forename: Quang D
authors.initials: QD
authors.lastname: Pham
authors.affiliation: Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
authors.forename: Michael
authors.initials: M
authors.lastname: Pickles
authors.affiliation: Research Department of Infection and Population Health, University College London, London, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: Phillips
authors.affiliation: Social and Mathematical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
authors.forename: Lucy
authors.initials: L
authors.lastname: Platt
authors.affiliation: Futures Institute, Glastonbury, CT, USA.
authors.forename: Carel
authors.initials: C
authors.lastname: Pretorius
authors.affiliation: Social and Mathematical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
authors.forename: Holly J
authors.initials: HJ
authors.lastname: Prudden
authors.affiliation: Department of Global Health and Population, Harvard School of Public Health, Boston, MA, USA ; Center for Health Decision Science, Harvard School of Public Health, Boston, MA, USA.
authors.forename: Joshua A
authors.initials: JA
authors.lastname: Salomon
authors.affiliation: Department of Virology, Erasmus Medical Center, Rotterdam, Netherlands.
authors.forename: David A M C
authors.initials: DA
authors.lastname: van de Vijver
authors.affiliation: Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
authors.forename: Sake J
authors.initials: SJ
authors.lastname: de Vlas
authors.affiliation: Epidemiological Modeling Group, Intellectual Ventures Laboratory, Bellevue, WA, USA.
authors.forename: Bradley G
authors.initials: BG
authors.lastname: Wagner
authors.affiliation: Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
authors.forename: Richard G
authors.initials: RG
authors.lastname: White
authors.affiliation: Kirby Institute, University of New South Wales, Sydney, Australia.
authors.forename: David P
authors.initials: DP
authors.lastname: Wilson
authors.affiliation: Kirby Institute, University of New South Wales, Sydney, Australia.
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.affiliation: U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
authors.forename: John
authors.initials: J
authors.lastname: Blandford
authors.affiliation: Center for Global Health and Development, Boston University, Boston, MA, USA ; Health Economics and Epidemiology Research Office, Department of Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
authors.forename: Gesine
authors.initials: G
authors.lastname: Meyer-Rath
authors.affiliation: Social and Mathematical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
authors.forename: Michelle
authors.initials: M
authors.lastname: Remme
authors.affiliation: Centre for Health Economics, University of York, York, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Revill
authors.affiliation: U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
authors.forename: Nalinee
authors.initials: N
authors.lastname: Sangrujee
authors.affiliation: Social and Mathematical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
authors.forename: Fern
authors.initials: F
authors.lastname: Terris-Prestholt
authors.affiliation: Department of HIV/AIDS, World Health Organization, Geneva, Switzerland.
authors.forename: Meg
authors.initials: M
authors.lastname: Doherty
authors.affiliation: Department of HIV/AIDS, World Health Organization, Geneva, Switzerland.
authors.forename: Nathan
authors.initials: N
authors.lastname: Shaffer
authors.affiliation: Department of HIV/AIDS, World Health Organization, Geneva, Switzerland.
authors.forename: Philippa J
authors.initials: PJ
authors.lastname: Easterbrook
authors.affiliation: Department of HIV/AIDS, World Health Organization, Geneva, Switzerland.
authors.forename: Gottfried
authors.initials: G
authors.lastname: Hirnschall
authors.affiliation: Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
authors.forename: Timothy B
authors.initials: TB
authors.lastname: Hallett
references.citation: Lancet. 2012 Dec 15;380(9859):2129-43
references.pmid: 23245605
references.citation: PLoS One. 2010 Jun 10;5(6):e11068
references.pmid: 20548786
references.citation: AIDS. 2013 Jun 1;27(9):1449-60
references.pmid: 23462221
references.citation: PLoS Med. 2011 Jul;8(7):e1001056
references.pmid: 21811403
references.citation: AIDS. 2011 Oct 23;25(16):1939-49
references.pmid: 21811137
references.citation: J Intern Med. 2011 Dec;270(6):532-49
references.pmid: 21929723
references.citation: PLoS Med. 2012;9(7):e1001245
references.pmid: 22802730
references.citation: Lancet. 2010 Oct 9;376(9748):1254-60
references.pmid: 20934597
references.citation: N Engl J Med. 2011 Aug 11;365(6):493-505
references.pmid: 21767103
references.citation: PLoS One. 2012;7(2):e30216
references.pmid: 22348000
references.citation: Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009153
references.pmid: 23633367
references.citation: Science. 2013 Feb 22;339(6122):966-71
references.pmid: 23430656
references.citation: PLoS Med. 2012;9(11):e1001347
references.pmid: 23185139
references.citation: PLoS One. 2012;7(12):e51993
references.pmid: 23284843
references.citation: Lancet Infect Dis. 2013 Apr;13(4):313-8
references.pmid: 23375420
references.citation: PLoS One. 2011;6(7):e21919
references.pmid: 21799755
references.citation: J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):26-35
references.pmid: 21068674
references.citation: PLoS One. 2013;8(2):e55312
references.pmid: 23457467
references.citation: PLoS Med. 2012;9(7):e1001250
references.pmid: 22807657
references.citation: AIDS. 2012 Sep 10;26(14):1840-3
references.pmid: 22781219
references.citation: AIDS. 2011 Sep 10;25(14):1753-60
references.pmid: 21412127
references.citation: AIDS. 2013 Jul 31;27(12):1839-46
references.pmid: 24179998
references.citation: J R Soc Interface. 2013 Aug 28;10(88):20130613
references.pmid: 23985734
references.citation: Lancet. 2010 Aug 14;376(9740):532-9
references.pmid: 20638713
references.citation: Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21271-6
references.pmid: 23223563
references.citation: PLoS One. 2012;7(5):e37125
references.pmid: 22615917
references.citation: N Engl J Med. 2013 Mar 7;368(10):886-9
references.pmid: 23425131
references.citation: Drug Alcohol Depend. 2012 Jun 1;123(1-3):122-31
references.pmid: 22138540
references.citation: BMC Public Health. 2012 Jun 25;12:296
references.pmid: 22520171
references.citation: PLoS Med. 2012;9(7):e1001231
references.pmid: 22807656
references.citation: PLoS Med. 2013 Oct;10(10):e1001534
references.pmid: 24167449
references.citation: J Infect Dis. 2014 Feb 1;209(3):431-40
references.pmid: 23990567
references.citation: Lancet. 2011 Jun 11;377(9782):2031-41
references.pmid: 21641026
references.citation: AIDS. 2013 Sep 24;27(15):2461-70
references.pmid: 23842132
references.citation: Lancet. 2009 Jan 3;373(9657):48-57
references.pmid: 19038438
references.citation: J Int AIDS Soc. 2012 Nov 19;15(2):17383
references.pmid: 23199799
references.citation: PLoS Med. 2011 Nov;8(11):e1001132
references.pmid: 22140367
references.citation: AIDS. 2014 Jan;28 Suppl 1:S61-72
references.pmid: 24468948
references.citation: PLoS One. 2012;7(11):e48726
references.pmid: 23144946
references.citation: J Infect Dis. 2013 Jun 15;207 Suppl 2:S57-62
references.pmid: 23687290